SI-BONE announced that Aetna has established a positive coverage policy for minimally invasive SI joint fusion.
The new policy covers minimally invasive arthrodesis of the sacroiliac joint (e.g., iFuse) to treat sacroiliac joint syndrome and sacroiliac joint pain. This decision was based upon extensive published clinical evidence demonstrating the safety and effectiveness of the iFuse Implant, including recently published 5-year results from 93 subjects from LOIS, a long-term prospective study (Long Term Outcomes from INSITE and SIFI).
The positive coverage policy further validates acceptance of iFuse as a treatment option for patients with chronic sacroiliac joint dysfunction. Aetna is the third-largest commercial health plan in the U.S. iFuse also has positive coverage from Blue Cross and Blue Shield, CIGNA and TRICARE.
“As a result of this positive coverage decision, Aetna’s 22 million medical plan members will have access to the iFuse procedure when deemed medically necessary by their surgeons,” said Jeffrey Dunn, President, CEO and Chairman at SI-BONE. “Aetna’s decision to cover MIS SI joint fusion with iFuse is a significant milestone and further expands access and adoption of this important treatment option for patients with SI joint dysfunction due to degenerative sacroiliitis or SI joint disruption.”